They showed that miR-200b-3p can target against zinc finger E-box-binding homeobox 1/2 (ZEB1/2), microfibril-associated glycoprotein 2 (MAGP2), mothers against decapentaplegic homolog 2 (SMAD2) and high mobility group box 3 (HMGB3), thereby inhibiting tumor growth, apoptosis and cellular mobility [54–57]. This evidence concerns the gene SMAD2 and neoplasm.